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Abstract 
Surface functionalization with antitransferrin receptor (TfR) mAbs has been suggested as the 
strategy to enhance the transfer of nanoparticles (NPs) across the blood-brain barrier (BBB) and to 
carry nonpermeant drugs from the blood into the brain. However, the efficiency of BBB crossing is 
currently too poor to be used in vivo. In the present investigation, we compared 6 different murine 
mAbs specific for different epitopes of the human TfR to identify the best performing one for the 
functionalization of NPs. For this purpose, we compared the ability of mAbs to cross an in vitro 
BBB model made of human brain capillary endothelial cells (hCMEC/D3). Liposomes 
functionalized with the best performing mAb (MYBE/4C1) were uptaken, crossed the BBB in vitro, 
and facilitated the BBB in vitro passage of doxorubicin, an anticancer drug, 3.9 folds more than 
liposomes functionalized with a nonspecific IgG, as assessed by confocal microscopy, 
radiochemical techniques, and fluorescence, and did not modify the cell monolayer structural or 
functional properties. These results show that MYBE/4C1 antihuman TfR mAb is a powerful 
resource for the enhancement of BBB crossing of NPs and is therefore potentially useful in the 
treatment of neurologic diseases and disorders including brain carcinomas. 
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Introduction 
In spite of decades of research, the specific transport of drugs and imaging agents to the brain 
remains challenging because of the efficiency of the blood–brain barrier (BBB), a tightly packed 
layer of endothelial cells that protect the brain from potentially harmful endogenous compounds and 
xenobiotics.1 Several strategies bypassing the BBB have been proposed,2, 3 but the potential benefits 
of such systems must be weighted against their impact on the defensive function of BBB. In this 
context, targeted delivery achieved by directly coupling a brain-targeting ligand to a drug molecule 
or by encapsulating drugs into brain-targeted nanoparticles (NPs) has been proposed as an 
innovative and noninvasive tool for delivering drugs to the brain. NP-mediated brain drug delivery 
might be achieved by functionalizing the NP surface with BBB targeting agents, thus allowing the 
NP to cross the BBB by exploiting the physiological mechanisms of transport.4 Transferrin 
receptor (TfR), also known as CD71, has received the greatest attention for use in target-mediating 
NP brain entry, owing to its expression on BBB endothelial cells for the regulation of brain uptake 
of iron.5, 6 
The purpose of this investigation was to identify, among a panel of antihuman TfR mAbs, the most 
efficient to promote BBB crossing of nanoliposomes (nano-LIPs)—colloidal vesicles formed by 
biodegradable and biocompatible phospholipids and sphingolipids frequently used as a delivery 
system for drugs. For this reason, 6 antihuman TfR mAbs, specific for different epitopes of the 
human TfR I, namely CB26 (IgG1), CBMIEL-2 (IgG1), MYBE/4G3 (IgG1), MYBE/5F5 (IgG1), 
MYBE/4C1 (IgG1), and CBMIEL-1 (IgM) were prepared. The criteria for selection were the mAb 
ability to cross an in vitro BBB model made up of human brain capillary endothelial cells 
(hCMEC/D3). The best performing mAb was used to functionalize LIP, and the permeability across 
the BBB model of the resulting functionalized NP was studied to verify their potential 
as nanocarriers for applications in the treatment of brain diseases. 
 
Experimental 
Materials 
Bovine brain sphingomyelin (Sm), cholesterol (Chol), and 1,2-distearoyl-sn-glycero-3-phospho-
ethanolamine-N-[maleimide(polyethyleneglycol)-2000] were purchased from Avanti Polar Lipids, 
Inc. (Alabaster, AL). N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoyl)-
sphingosyl-phosphocholine (BODIPY-Sm) was from Molecular Probes (Life Technologies, 
Carlsbad, CA). N-acetyl-cysteine, Sepharose CL-4B, doxorubicin hydrochloride(DOX), 3-(4,5-
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dimetiltiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),4-(2-hydroxyethyl) piperazine-1-
ethanesulfonic acid (HEPES), and Triton X-100 were purchased from Sigma-Aldrich. Tritiated 
sphingomyelin ([3H]-Sm) was from PerkinElmer (Waltham, MA). Amicon Ultra-15 centrifugal 10K 
filter devices and polycarbonate filters for the extrusion procedure were purchased from Merck 
Millipore (Billerica, MA). The Thermobarrel Extruder was from LipexBiomembranes (Vancouver, 
BC, Canada). Purified rat antimouse RI7217 was from BioLegend (San Diego, CA). Ultrapure 
and deionized water were obtained from Direct-Q5n system (Millipore, Italy). All other chemicals 
were reagentgrade. All the stock solutions for cell cultures were from Euroclone (Milano, Italy). 
The Elisa kits for IgM and IgG quantitative detection were from eBioscience (San Diego, CA). 
Texas Red-X phalloidin and 4′,6-diamidino-2-phenylindole were from Molecular Probes (Life 
Technologies, Carlsbad, CA). 
Methods 
Preparation of Antihuman TfR mAbs 
A panel of specific murine mAbs was produced through immunization with murine L-fibroblasts 
transfected with the human TfR-1 (L-CD71+), obtained as described.7 Female Balb/c mice were 
injected twice intraperitoneally with 5 × 106 cells. Five days before somatic fusion with the 
P3.X63.Ag8/653 myelomaline, mice were injected intravenously with 2 × 106 cells. Four days after 
the last injection, the spleen was removed for fusion using conventional techniques.8The reactivity 
of the individual anti-CD71 mAbs was analyzed by cytofluorimetric analysis (see later). Positive 
clones underwent 2 rounds of cultures after limiting dilution and were then expanded in massive 
cultures. Individual clones were tested for isotype by means of Outcherlony technique. The mAbs 
identified were CB26 (IgG1), CB-MIEL-2 (IgG1), MYBE/4G3 (IgG1), MYBE/5F5 (IgG1), CB-
MIEL-1 (IgM), and MYBE/4C1 (IgG1). Each mAb was purified using an HPLC technique as 
described.9 The purified mAbs were then sterilized by 0.22-μm filtration (Millipore 
Polyethersulfone Millex-GP Syringe Filter Unit, radiosterilized) and detoxified by Detoxi-
Gel Endotoxin Removing Gel (Thermo Scientific). The work for the production of the murine 
mAbs was performed under the control of a local Committee of Animal Care, after a permission 
issued by the Istituto Superiore di Sanità (National Institute of Health, Rome). 
Cytofluorimetric Analysis 
L-CD71+ cells (2.5 × 105) washed in phosphate-buffered saline (PBS) containing 1% bovine serum 
albumin and NaN3 were incubated with the panel of anti-CD71 mAbs (1 h, 4°C). Unbound mAb 
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was eliminated by washing twice and incubated 30 min, 4°C with fluorescein 
isothiocyanate (FITC)-conjugated F(ab')2 goat antimouse IgG+IgM (Jackson Immuno-Research 
Laboratories, West Grove, PA). The samples were washed, resuspended in PBS, and acquired on an 
FACScan (Becton-Dickinson, San Jose, CA) using CellQuest Software (Becton-Dickinson). Data 
WinMDI 2.9 software collected were analyzed using a WinMDI 2.9 software (Scripps Research 
Institute, La Jolla, CA). IB4 was analyzed with a similar approach using murine NIH-3T3 cells 
trasfected with human CD38 (NIH-3T3/CD38+). Mock-transfected L-cells were used as negative 
controls. 
Preparation of LIP Functionalized With mAbs (MYBE/4C1-LIP, IB4-LIP, and RI7217-LIP) 
LIPs were prepared in 10 mM PBS, pH 7.4, using Sm/Chol/1,2-distearoyl-sn-glycero-3-phospho-
ethanolamine-N-[maleimide(polyethyleneglycol)-2000 (49.5:49.5:1 molar ratio), by extrusion of the 
multilamellar vesicles through 100-nm pore-size filters, as previously described.10 For preparation 
of fluorescently labeled LIP, 0.5 molar% of total Sm was substituted with BODIPY-Sm. For 
preparing radiolabeled LIP, 0.001 molar% of [3H]-Sm (100 μCi/mL) was added as a tracer to track 
lipid distribution by measuring radioactivity. For the covalent coupling to maleimide-containing 
LIP, MYBE/4C1, IB4, and RI7217 were thiolated, as described.10 Thiolated mAbs were then 
incubated with LIP (4 mM) overnight at 25°C at a 1:1000 molar ratio of mAbs/phospholipids. 
Unbound mAbs were removed by using gel exclusion chromatography (Sepharose 4B-CL column). 
The amount of mAb bound to LIP was quantified using the Bradford assay.11 Phospholipids in final 
samples were quantified by using Stewart's assay.12 mAb-functionalized LIPs are called IB4-LIP, 
MYBE/4C1-LIP, and RI7217-LIP. 
Preparation of DOX-Loaded LIP (MYBE/4C1-DOX-LIP, IB4-DOX-LIP, and RI7217-DOX-LIP) 
The procedure described by Sakakibara et al.13 was followed with only small changes. LIPs 
composed as previously described were prepared in ammonium sulfate (500 mM, pH 5.5) and 
extruded through polycarbonate membranes of 100-nm pores. LIPs were then dialyzed 
against HEPES (10 mM, pH 7.4) and incubated with DOX for 1 h at 65°C. Free DOX was removed 
by gel filtration (Sepharose 4B-CL column). DOX loading was quantified fluorometrically (λex = 
495 nm; λem = 592 nm) after vesicle disruption with 0.1% Triton X-100.14 To obtain DOX 
concentration in the solution, fluorescence intensities were compared with a previously established 
calibration curve for DOX in HEPES (10 mM, pH 7.4). Drug loading was calculated using the 
following equation: drug loading% = DOX concentration in NP solution or NP concentration in the 
same solution × 100. LIPs were then functionalized with mAbs as described previously. 
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Size and Charge Characterization of LIP 
Size, ζ-potential, polydispersity index, and stability were analyzed by dynamic light 
scattering (DLS), as described previously.15 The reported data are the mean of at least 5 different 
measurements. 
Cell Cultures 
Immortalized hCMEC/D3 were provided by the Institut National de la Santé et de la Recherche 
Médicale, Paris, France) and cultured as previously described.16 
Cellular Uptake of mAb-Functionalized LIP by Human Brain Endothelial Cells 
hCMEC/D3 (65,000 cells cm−2) were cultured for 2 days on rat type I collagen-coated cover slips 
(diameter, 22 mm) positioned in culture dishes and then incubated with fluorescent (BODIPY-Sm) 
IB4-LIP or MYBE/4C1-LIP (30 μg mL−1of mAbs) at 37°C. After 2 h, cells were treated as 
described.10 Cellular uptake of LIP was assessed by using an inverted confocal microscope (Carl 
Zeiss Meditec AG, Jena, Germany, model Cell Observer), equipped with a Plan-Neofluar 63x /1.4 
numerical aperture oil immersion objective (Zeiss) and interfaced with a spinning-disk module 
(Yokogawa CSU X1) and with an EMCCD camera (Evolve 512; Photometrics, Tucson, AZ). 
Evaluation of Anti-TfR mAbs or LIP or DOX Crossing of Human Brain Endothelial Cells BBB 
Model 
hCMEC/D3 cells (passages 25-35) were seeded on 12-well transwell inserts coated with type I 
collagen at a density of 7 × 104 cells/cm2 and cultured as described previously. Cells were treated 
when the transendothelial electrical resistance (TEER) value (measured by EVOMX meter, STX2 
electrode; World Precision Instruments, Sarasota, FL) was highest. The functionality of cell 
monolayers was assessed by measuring the endothelial permeability (EP) of [14C]-sucrose and [3H]-
propranolol as described.17 Cells were incubated with different mAbs or radiolabeled LIP 
functionalized with mAbs or LIP functionalized with mAbs and loaded with DOX or free DOX 
(300 nmols/well of lipids, 15 μg/well of mAb, and 2.5 μg/well of DOX). After 2 h, the amount of 
anti-TfR mAbs or LIP or DOX in the 2 chambers was measured by different techniques. The 
amount of anti-TfR mAbs was measured using a specific ELISA kit according to the manufacturer's 
instructions, by using for each mAb a specific calibration curve constructed with different quantities 
(from 100 to 1.5 ng mL−1) of the mAb analyzed. The amount of LIP was measured by radioactivity 
counting. The amount of DOX was measured by fluorescence, after vesicle disruption as reported 
previously.14 After this, the EP across the cell monolayers was calculated as described.17 For DOX, 
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results are expressed also as the percentages of the total applied dose of DOX quantified in the 
lower chamber. 
Assessment of LIP Biocompatibility 
hCMEC/D3 cells were treated with different LIP samples (MYBE/4C1-LIP, IB4-LIP, MYBE/4C1-
DOX-LIP, and IB4-DOX-LIP) or with free DOX at DOX concentration of 6, 12.5, and 25 μg 
mL−1 for 2 h or 72 h, and the LIP biocompatibility was evaluated by MTT assay18 and lactate 
dehydrogenase(LDH) test19 to evaluate the mitochondrial activity and the release of the cytoplasmic 
enzyme LDH as a consequence of membranes leaking of damaged or dead cells, respectively. MTT 
solution was added to the cells for a final concentration of 0.5 mg mL−1, and the cells were 
incubated at 37°C for 2 h. After incubation, ethanol was added to each well to dissolve 
the formazancrystals formed. Absorbance at 550 nm was measured with a microplate reader 
(Victor3 1420 multilabel counter; PerkinElmer). Untreated cells were used as a negative control. 
Each sample was analyzed at least 3 times. LDH was analyzed using the cytotoxicity detection kit 
according to the manufacturer's instruction (Roche, Germany). Absorbance at 490 nm was 
measured with a microplate reader (Victor3 1420 multilabel counter; PerkinElmer). The relative 
amount of released LDH was normalized to the total amount of LDH of control cells completely. 
Each sample was analyzed at least in triplicate. Moreover, TEER was also determined on 
hCMEC/D3 cells seeded on transwell inserts after 2 h of treatment with different LIP to assess the 
effect of LIP on monolayer integrity. 
Statistical Analysis 
All experiments were carried out at least 3 times. Statistical analyses were performed using 
OriginPro8 (OriginLab Corporation, Northampton, MA). Data were compared using the unpaired 
Student t-test and expressed as means ± SEM. 
 
Results 
Evaluation of the Reactivity of anti-TfR mAbs 
The reactivity and specificity of 6 different anti-TfR mAbs were tested in indirect immune 
fluorescence by using as targets murine L-fibroblasts transfected with human CD71 (L-CD71+). 
Cytofluorimetric analysis indicated that the binding of the purified mAbs was specific, and the 
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reactivity was maintained up until the concentration of 10 μg/mL. Only exception was for the 
CBMIEL-2 mAb (Fig. 1). 
 
 
Figure 1. Comparative analysis of the different anti-CD71 mAbs under analysis. The reactivity and specificity of the 
individual mAbs are assessed by using murine fibroblasts transfected with human CD71 (L-CD71+). Tests were done on 
a FACScan™ (Becton Dickinson) using an FITC-labeled F(ab')2 antimurine IgG antibody. Black profiles indicate the 
expression levels of the mAbs under analysis. Gray profiles are referred to an irrelevant control Ig (background). The 
mAbs were equalized for concentration (a: 1 mg/mL; b: 0.1 mg/mL; c: 0.01 mg/mL; and d: 0.001 mg/mL). X-axis: 
fluorescence intensity/cells and y-axis: number of cells registered/channel. 
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Evaluation of Anti-TfR mAbs Crossing of a BBB Model 
Six murine mAbs specific for different epitopes of the human TfR I have been evaluated for their 
ability to cross an in vitro BBB model made up of human brain capillary endothelial cells 
(hCMEC/D3). Of the panel of specific TfR mAbs prepared, the MYBE/4C1 mAb provided the best 
results in terms of BBB crossing (Fig. 2). 
 
 
Figure 2. Transcytosis of anti-TfR mAbs. 7 × 104 hCMEC/D3 cells were incubated with 6 anti-TfR mAbs (CB26, CB-
MIEL-2, MYBE/4G3, MYBE/5F5, CB-MIEL-1, and MYBE/4C1) and with a nonspecific IgG (IB4) for 3 h at 37°C, 
5% CO2. The permeability of mAbs across the cell monolayer was analyzed by specific Elisa kit. Each value is the 
mean of at least 3 independent experiments, and the SDs of means are presented as bars. **p < 0.01. 
 
Preparation and Characterization of LIP 
LIPs were functionalized with MYBE/4C1 mAb, the best performing anti-TfR mAb in terms of 
BBB model crossing, and, for comparison, with IB4, a nonspecific IgG, and with RI7217, an 
antimouse TfR mAb commercially available. To be linked to LIP surface by covalent coupling, 
mAbs were thiolated by Traut reaction. SDS–PAGE experiments were run to analyze the quality of 
MYBE/4C1 mAb after thiolation. Results showed that thiolation did not affect the integrity of the 
mAb (Fig. S-2). Moreover, a dot blot experiment with human TfR was performed with MYBE/4C1 
mAb before and after thiolation to verify if the reaction affects the affinity of the mAb to its target. 
Results showed that the thiolated MYBE/4C1 mAb retained the ability of native antibody to bind 
human TfR (Fig. S-3). The structure of immunoLIP is depicted in Figure 3. LIPs were 
functionalized with mAb by covalent coupling of the thiolated mAb on the maleimide moiety 
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protruding from the LIP surface. This reaction allowed the linkage of 40-45 mAb molecules on the 
surface of each LIP, as assessed by Bradford assay. The number of mAbs conjugated per LIP was 
based on the assumption that a 100-nm–size liposome contains ∼100,000 molecules of 
phospholipids.20 To verify the presence of the antihuman TfR mAb on LIP surface, a dot blot with 
human TfR was run. Results showed that the MYBE/4C1 mAb is present on LIP and still binds 
human TfR (Fig. S-3). 
 
 
 
Figure 3. Hypothetical structure of LIPs double functionalized with mAbs and with DOX. DOX was incorporated into 
the LIPs after extrusion by a transmembrane pH gradient. mAbs were linked to LIPs by covalent coupling after 
thiolation (see Methods section for details). 
 
 
To investigate the ability of these nanosystems to deliver drugs, DOX was used as a model drug to 
be incorporated into LIP before its functionalization with mAbs. Incorporation efficiency was 230 
μg of DOX/mg of lipids. The size and charge of different LIPs prepared in the present investigation 
are reported in Table 1. All LIP preparations resulted monodispersed (polydispersity index < 0.1) 
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and negatively charged. Functionalization with mAbs and loading with DOX caused a slight 
increase of the LIP size, as already reported. All the preparations remained stable in size and charge 
for up to 7 days (Table 1) as accessed by DLS measurements. 
 
 
Table 1. Size and Charge of LIPs 
Sample Size (nm) ± 
SD 
Size (nm) ± SD at 
day 7 
Z-Pot (mV) ± 
SD 
Z-Pot (mV) ± SD at 
day 7 
LIP 104 ± 4 106 ± 6 −25.5 ± 0.8 −23.4 ± 2.2 
MYBE/4C1-LIP 125 ± 5 124 ± 3 −23.4 ± 1.2 −22.8 ± 1.0 
IB4-LIP 123 ± 6 126 ± 3 −21.1 ± 2.3 −22.3 ± 1.5 
RI7217-LIP 121 ± 2 119 ± 5 −27.1 ± 3.2 −27.3 ± 2.5 
MYBE/4C1-DOX-
LIP 
142 ± 4 146 ± 5 −18.2 ± 4.0 −18.4 ± 3.1 
IB4-DOX-LIP 138 ± 3 142 ± 4 −15.2 ± 3.8 −15.6 ± 2.2 
RI7217-DOX-LIP 133 ± 6 133 ± 5 −24.3 ± 2.5 −23.9 ± 2.0 
Mean diameter and Zeta-potential (Z-pot) were obtained by DLS and Zeta-potential analyzer for different LIPs before 
and after functionalization with mAbs and DOX, at day 0 and 7 after preparation. 
 
 
Cellular Uptake of mAbs-Functionalized LIP by Human Brain Endothelial Cells 
To investigate the cellular uptake of mAbs-functionalized LIP on the in vitro BBB model, 
BODIPY-Sm, a fluorescent phospholipid, was incorporated into LIP before functionalization with 
mAbs. Cellular uptake of fluorescent IB4-LIP and MYBE/4C1-LIP was investigated qualitatively 
by confocal microscopy on hCMEC/D3 cells. Confocal microscopy images reveal that the uptake of 
LIP was higher after functionalization with MYBE/4C1. Furthermore, these NPs did not induce 
changes in actin organization of hCMEC/D3 cells (Fig. 4). 
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Figure 4. Confocal spinning disk microscopy of hCMEC/D3 cells after incubation with fluorescent IB4-LIP (a) (anti-
human CD38, an irrelevant IgG control) or MYBE/4C1-LIP (b) (30 μg mL−1 of antibodies) at 37°C, 5% CO2 saturation. 
Cells were incubated with phalloidin to visualize the actin filaments (red fluorescence); nuclear staining was highlighted 
by 4′,6-diamidino-2-phenylindole (blue fluorescence). 
 
 
Permeability of mAbs-Functionalized LIP and DOX Across Human Brain Endothelial BBB 
Cellular Model 
The permeability of MYBE/4C1-LIP across a BBB in vitro model made of hCMEC/D3 cells was 
quantitatively evaluated using [3H]-Sm-labeling and radioactivity counting and compared with the 
permeability of free DOX and of LIP functionalized with a nonspecific mAb (IB4-LIP) and with 
another antimouse TfR mAb, commercially available (RI7217-LIP). hCMEC/D3 cells, grown on 
transwell membrane inserts, were incubated with different LIP preparations on day 12, when the 
maximal TEER value was registered (63 ± 5 Ω ⋅ cm2). Transport of [14C]-sucrose and [3H]-
propranolol was measured to access the formation of junctions with EP values of 1.48 × 
10−3 cm/min and 3.51 × 10−3cm/min, respectively, in agreement with the values reported in the 
literature.21 NPs were added in the upper compartment, and the radioactivity was measured in the 
lower compartment after 2-h incubation. The EP across the cell monolayers was higher for 
MYBE/4C1-LIP (3.69 ± 0.078 × 10−5 cm/min), as compared with IB4-LIP (7.69 ± 0.021 × 
10−6 cm/min) (p < 0.01) and also to RI7217-LIP (3.31 ± 0.07 × 10−5 cm/min) (p < 0.01) (Fig. 5). 
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Figure 5. Cellular permeability of LIP and free DOX through hCMEC/D3 cell monolayers. 7 − 104 cells were 
incubated with free DOX or with LIP functionalized with mAbs (IB4, MYBE/4C1, or RI7217) and with DOX and 
radiolabeled with [3H]-Sm for 3 h at 37°C, 5% CO2. The permeability of LIP across the cell monolayer was calculated 
for [3H]-Sm (gray bars) and for DOX (black bars). Each value is the mean of at least 3 independent experiments, and 
the SDs of means are presented as bars. **p < 0.01 versus IB4-LIP, ++p < 0.01 versus RI7217-DOX-LIP, $$p < 0.01 
versus free DOX (Student t-test). 
 
 
DOX PE was also investigated through the same in vitro BBB model by using mAbs-functionalized 
LIP loaded with DOX. Again, LIPs were added on the apical side of a transwell system made of 
hCMEC/D3 cells, and DOX in the lower compartment was quantified. The amount of DOX in the 
lower compartment was 0.95% ± 0.06% for MYBE/4C1-DOX-LIP, 0.24% ± 0.04% for IB4-DOX-
LIP, and 0.86% ± 0.08% for RI7217-DOX-LIP. Also the EP of DOX is higher with MYBE/4C1-
DOX-LIP (4.18 ± 0.14 × 10−5 cm/min), as compared with IB4-DOX-LIP (7.38 ± 0.12 × 
10−6 cm/min) (p < 0.01), to RI7217-LIP (2.71 ± 0.30 × 10−5 cm/min) (p < 0.01) and to free DOX 
(6.65 ± 1.60 × 10−6 cm/min) (Fig. 5). To understand if the enhanced BBB in vitro passage of 
MYBE/4C1-LIP compared with RI7217-LIP is because of a higher affinity of the first mAb to 
human TfR, the binding of the 2 mAbs toward human TfR was investigated by surface plasmon 
resonance. The calculated KD was 64.3 and 14.5 nM for MYBE/4C1 and RI7217, respectively 
(Fig. S-1). 
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Cytotoxicity 
hCMEC/D3 cells were treated with different mAbs-functionalized LIP loaded or not with DOX (25 
μg mL−1) for 2 h, and cell viability was assessed by MTT assay and LDH test. Treatment did not 
affect the viability of endothelial cells (Fig. S-4). Moreover, after hCMEC/D3 incubation with LIP, 
the TEER value did not change within the experimental error (<3%). The effect of DOX released by 
LIP was observed after 72 h at different DOX concentrations. As shown in Figure 6, it was dose 
dependent. The calculated IC50 of MYBE/4C1-DOX-LIP, IB4-DOX-LIP, and free DOX was 38.4 ± 
4.0, 39.0 ± 4.0, and 8.7 ± 0.7 μg mL−1, respectively. 
 
 
 
Figure 6. Cytotoxicity of mAbs and DOX-functionalized LIP or free DOX on hCMEC/D3. Cells were incubated with 
MYBE/4C1-DOX-LIP or IB4-DOX-LIP or free DOX (6, 12.5, and 25 μg mL−1 of DOX concentration) for 72 h, and the 
mitochondrial activity and LDHleakage were determined by MTT assay (a) and LDH assay (b), respectively. The 
results are reported as percentage respect to the untreated cells (control). The data are reported as the mean ± SEM of 
triplicate experiments. The results were compared by Student t-test. - =untreated cells. 
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Discussion 
The entry of several potentially therapeutic agents into the brain is restricted by the presence of the 
BBB. The use of receptor-mediated transcytosis is one of the strategies proposed to carry 
therapeutic agents from the blood into the brain.22 In particular, the functionalization of NP with 
mAbs recognized by receptors overexpressed on BBB endothelial cells has been reported to 
enhance BBB passage both of NP and NP-embedded drugs.23 Among all the receptors analyzed, 
TfR is the most widely studied for BBB targeting.24Recently, our group designed multifunctional 
LIP for Alzheimer disease therapy that are able to cross the BBB, thanks to the functionalization 
with RI7217, an antimouse TfR mAb.10 The literature contains multiple examples of NP 
functionalized with antimouse or antirat TfR mAbs for crossing the BBB25, 26, 27, 28, 29, 30; however, 
very few examples concern the functionalization of NP with antihuman TfR mAbs,31, 32, 33 and to 
the best of our knowledge, none of them is designed to facilitate crossing of the BBB by NP. Even 
if the homology between mouse and human receptor is 86%,34 the use of antihuman TfR mAb-
functionalized NP as brain drug delivery carriers is highly regarded. For this reason, we produced a 
panel of 6 antihuman TfR mAbs in our study and tested their ability to cross an in vitro BBB 
cellular model made up of the human brain capillary endothelial cell line hCMEC/D3, known as 
expressing TfR.21 The best performing mAb, MYBE/4C1, was used to functionalize LIP to prepare 
brain delivery carriers. LIPs were selected as delivery vehicles because they are the most common 
NP currently used for targeted drug delivery in vivo.35, 36 They are nontoxic, nonimmunogenic, 
biocompatible, biodegradable, and can be grafted with PEG on their surface to avoid rapid 
clearance by the reticuloendothelial system. Moreover, these carriers can store drugs or imaging 
agents in the hydrophobic shell or in the aqueous interior, depending on the nature of the drug or of 
the contrast agent being carried. The lipidic matrix used in the present investigation (Chol and Sm) 
was chosen because already used for in vivo experiments, displaying high circulation times in 
blood, biocompatibility, and resistance to hydrolysis.37 A thiol-maleimide covalent coupling was 
exploited for mAb functionalization. Indeed, our group proved the superior efficiency of covalent 
coupling as compared with biotin/streptavidin ligation to link mAb to LIP surface to overcome a 
BBB in vitro model.10 Reaction conditions were optimized to obtain 40-45 mAb molecules exposed 
on the surface of each LIP, a density considered as optimal for brain targeting.25 DLS analysis 
showed that LIPs prepared have a size below 200 nm, which in a future in vivo application may 
allow the NP to move at appreciable rates through the brain extracellular space.38 Moreover, the 
negative charge of the resulting LIP is a good feature for using them as brain carriers because it is 
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reported that cationic NPs are more toxic than neutral and negatively charged NP toward BBB 
cells.39 
The results of the present work demonstrated that the presence of MYBE/4C1 mAb on the surface 
enhanced the crossing of LIP on hCMEC/D3 BBB model. The transcytosis ability of these LIPs 
was investigated in vitro by measuring the permeability values of both 3H-Sm used as LIP tracer 
and DOX embedded in LIP across a monolayer of hCMEC/D3 cells. A great improvement in the 
amount of DOX carried through the BBB by using MYBE/4C1-DOX-LIP instead of the free drug is 
clearly evident, as already showed for other LIPs carrying DOX.40 Moreover, EP values of LIP 
functionalized with MYBE/4C1 are higher than the ones obtained using LIP functionalized with a 
commercially available rat antimouse TfR (RI7217). Surface plasmon resonance experiments 
suggest that these results are because of a higher affinity of MYBE/4C1 mAb to human TfR 
compared with RI7217. This finding is a confirmation of the choice of adopting human TfR as a 
target in functionalizing NP to cross the human BBB in vitromodel. Moreover, cell viability and 
monolayer integrity were not altered by the treatment. 
To validate the suitability of such NP as brain drug carriers, DOX was embedded in MYBE/4C1-
LIP. DOX was the first drug to be delivered by LIPs to brain tumors.41 Many studies indicated that 
therapy with DOX bound to NP offers a therapeutic potential for the treatment of human brain 
cancer.42, 43, 44, 45 DOX displays in vitro an excellent antineoplastic activity against brain tumors, but 
its clinical use for brain cancer is in fact limited because of severe systemic side effects46 and 
because it is extruded by P-glycoprotein (ABCB1) in BBB cells.47 The incorporation of DOX in NP 
may limit the side effects of the free drug and facilitate the passage of the BBB. Here, DOX 
incorporation was obtained by exploiting a reported procedure.13, 14, 48 To this aim, a transmembrane 
pH gradient was generated using a solution of ammonium saltsat acidic pH to induce protonation of 
DOX and precipitation in the interior aqueous medium of LIP. The adoption of this procedure 
yielded a very high incorporation efficiency. 
Interestingly, PE values obtained when quantifying DOX transport across the BBB model are very 
similar to values obtained when quantifying radioactivity of radiolabeled LIP. These results support 
the view that LIPs cross the BBB intact in an in vitro model. Significant is the observation that 
IC50 value of DOX embedded in LIP was higher than that of free DOX, suggesting the possibility of 
using such LIP to prevent the side effects of free drug against BBB cells. 
 
16 
 
Conclusions 
The present in vitro study shows that LIP functionalized with MYBE/4C1, an antihuman TfR mAb, 
could serve as nanovectors for delivering of drugs across the BBB to the brain. The enhanced BBB 
crossing of the incorporated anticancer drug doxorubicin suggests the potential use of these NPs for 
the treatment of brain tumors. 
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